Replies to post #659 on NuPathe Inc (fka PATH) (PATH)

[surf1944]

8:26AM On The Wires (WIRES) : NuPathe (PATH) announced the co has initiated dosing of patients for NP101-015, a Phase 1 study of ZECUITY (sumatriptan iontophoretic transdermal system) in adolescents with a history of migraine attacks. This open label, single-dose study will assess the safety, pharmacokinetics, and tolerability of ZECUITY in adolescent migraine patients.